Aandeel ELTX ELICIO THERAPEUTICS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Elicio Therapeutics, Inc.

Aandelen

ELTX

US28657F1030

slotkoers Nasdaq
Andere beurzen
 00:00:00 14-06-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
8,17 USD -3,77% Intraday-grafiek van Elicio Therapeutics, Inc. +0,25% -2,04%
23/05 Elicio Therapeutics kondigt voorlopige gegevens aan van de lopende AMPLIFY-7P Fase 1a-studie van ELI-002 7P bij patiënten met mKRAS-gedreven vaste tumoren op de 2024 ASCO Annual Meeting CI
15/05 Elicio Therapeutics, Inc. rapporteert winstresultaten voor het eerste kwartaal dat eindigde op 31 maart 2024 CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics : AMPLIFY 7P, a first in human safety and efficacy trial of adjuvant mKRAS specific lymph node targeted Amphiphile ELI 002 7P vaccine in minimal residual disease positive pancreatic and colorectal cancer patients (ASCO 2024 – Scientific Poster)
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-Driven Solid Tumors at the 2024 ASCO Annual Meeting
Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Elicio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
Elicio Therapeutics, Inc. to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing Amplify-201 Phase 1 Study of ELI-002 and ElI-008 at the AACR Annual Meeting
Elicio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Elicio Therapeutics, Inc. announced that it has received $5.999999 million in funding from Gkcc, LLC
Elicio Therapeutics, Inc. announced that it expects to receive $5.999999 million in funding from Gkcc, LLC
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
Elicio Therapeutics, Inc. Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
Elicio Therapeutics Reports First Patient Dosed in Mid-Stage Pancreatic Cancer Trial
Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
Elicio Therapeutics, Inc. Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers ELTX
  4. Nieuws Elicio Therapeutics, Inc.
  5. Andere talen